Electrochaea sells biomethane reactor to Again A/S
Archaeal Power-to-biomethan producer Electrochaea GmbH has sold a BioCat bioreactor to the Danish CCU specialist Again A/S.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1163 entries already.
Entries by Thomas Gabrielczyk
Flindr Therapeutics BV secures €20m Series A financing
/in News/by Thomas GabrielczykOss-based oncology company Flindr Therapeutics BV has secured €20m to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.
Nordic Bioproducts Group opens its first production facility
/in News/by Thomas GabrielczykFinnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology
Swiss Biotech Report reporting record turnover
/in News/by Thomas GabrielczykThe Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn.<span style="mso-ansi-language:EN-US" lang="EN-US"> Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and […]
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
/in News/by Thomas GabrielczykIpsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.
SeaBeLifeSeabelife SAS to develop next-gen dry AMD drug
/in News/by Thomas GabrielczykFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
Seabelife SAS to develop next-gen dry AMD drug
/in News/by Thomas GabrielczykFrench drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.
AmphiStar BV secures €6m to expand production
/in News/by Thomas GabrielczykWaste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).
Naobios and Sumagen partner to develop HIV vaccine
/in News/by Thomas GabrielczykVaccine maker Sumagen Co. Ltd has launched a cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.<br /> <br /><b><br /></b>
Solar Foods starts Factory01
/in News/by Thomas GabrielczykFinnish Solar Foods Oy has started microbial production of its protein powder Solein in Factory 01, Solar Foods’ first commercial-scale production facility in Vantaa, Finland.